β-2 microglobulin as a biomarker for peripheral artery disease
The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
1. A method for qualifying peripheral artery disease status in a subject comprising:
(a) measuring lysozyme in a biological sample from the subject; and
(b) correlating the measurement or measurements with peripheral artery disease versus non-peripheral artery disease.
2. The method of claim 1 , further comprising measuring β2-microglobulin.
3. The method of claim 1 , wherein said measurement or measurements of a biomarker is performed using mass spectrometry or an immunoassay.
4. The method of claim 1 , further comprising measuring cystatin C or β2-microglobulin.
5. The method of claim 3 , wherein mass spectrometry is SELDI-MS.
6. The method of claim 1 , wherein the sample is blood, serum, or plasma.
7. The method of claim 1 , wherein the correlating is performed by executing a software classification algorithm.
8. The method of claim 1 , further comprising: (c) reporting the status to the subject.
9. The method of claim 1 , further comprising: (c) recording the status on a tangible medium.
10. The method of claim 1 , further comprising: (c) managing subject treatment based on the status.
11. The method of claim 1 , further comprising: (d) measuring the at least one biomarker after subject management and correlating the measurement with disease progression.